Cancer Treatment Reviews
Volume 36, Issue 2 , Pages 110-121, April 2010

Treatment of the pregnant mother with cancer: A systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: Hematological tumors

  • Hatem A. Azim Jr.

      Affiliations

    • Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
    • Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Address: 55 Abdel Monem Riad Street, Mohandeseen, Cairo, Egypt. Tel.: +20 2 33026814; fax: +20 2 33028656.
    • ,
  • Nicholas Pavlidis

      Affiliations

    • Department of Medical Oncology, Ioannina University, Ioannina, Greece
    • ,
  • Fedro A. Peccatori

      Affiliations

    • Department of Medicine, Division of Hematology–Oncology, European Institute of Oncology, Milan, Italy

Received 11 September 2009; received in revised form 9 November 2009; accepted 15 November 2009. published online 17 December 2009.

Summary 

Managing pregnant patients with hematological tumors pose even more conflicts compared to solid tumors. Unlike the majority of solid tumors, hematological malignancies are potentially curable; hence it is important to deliver the best treatment options available, which sometimes could be too aggressive to deliver during pregnancy.

In part II, we report the results of women with hematological malignancies treated with systemic therapies during the course of pregnancy. Lymphoma, acute leukemia and chronic myeloid leukemia were the most commonly treated.

We discuss the safety of the different regimens reported and propose alternatives to standardized approaches in case they pose significant risk to the pregnancy and/or the fetus.

Keywords: Leukemia in pregnancy, Lymphoma in pregnancy, Rituximab, Chemotherapy, Safety

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0305-7372(09)00178-9

doi:10.1016/j.ctrv.2009.11.004

Cancer Treatment Reviews
Volume 36, Issue 2 , Pages 110-121, April 2010

Article Tools